申请人:Novo Nordisk HealthCare AG
公开号:US20170239362A1
公开(公告)日:2017-08-24
The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.